Hogg, Simon J. et al. published their research in Molecular Cell in 2021 | CAS: 1373423-53-0

Ethyl 3-((6-(4,5-dihydro-1H-benzo[d]azepin-3(2H)-yl)-2-(pyridin-2-yl)pyrimidin-4-yl)amino)propanoate (cas: 1373423-53-0) belongs to pyrimidine derivatives. Pyrimidines are isomeric with two other forms of diazines: pyridazine, with the nitrogen atoms in the 1 and 2 positions; and pyrazine, with the nitrogen atoms in the 1 and 4 positions. Pyrimidine derivatives have been used in a wide variety of pharmaceuticals including general anesthetics, anti-epilepsy medication, anti-malaria medication, drugs for treating high blood pressure, and HIV medication.COA of Formula: C24H27N5O2

Targeting histone acetylation dynamics and oncogenic transcription by catalytic P300/CBP inhibition was written by Hogg, Simon J.;Motorna, Olga;Cluse, Leonie A.;Johanson, Timothy M.;Coughlan, Hannah D.;Raviram, Ramya;Myers, Robert M.;Costacurta, Matteo;Todorovski, Izabela;Pijpers, Lizzy;Bjelosevic, Stefan;Williams, Tobias;Huskins, Shannon N.;Kearney, Conor J.;Devlin, Jennifer R.;Fan, Zheng;Jabbari, Jafar S.;Martin, Ben P.;Fareh, Mohamed;Kelly, Madison J.;Dupere-Richer, Daphne;Sandow, Jarrod J.;Feran, Breon;Knight, Deborah;Khong, Tiffany;Spencer, Andrew;Harrison, Simon J.;Gregory, Gareth;Wickramasinghe, Vihandha O.;Webb, Andrew I.;Taberlay, Phillippa C.;Bromberg, Kenneth D.;Lai, Albert;Papenfuss, Anthony T.;Smyth, Gordon K.;Allan, Rhys S.;Licht, Jonathan D.;Landau, Dan A.;Abdel-Wahab, Omar;Shortt, Jake;Vervoort, Stephin J.;Johnstone, Ricky W.. And the article was included in Molecular Cell in 2021.COA of Formula: C24H27N5O2 The following contents are mentioned in the article:

To sep. causal effects of histone acetylation on chromatin accessibility and transcriptional output, we used integrated epigenomic and transcriptomic analyses following acute inhibition of major cellular lysine acetyltransferases P300 and CBP in hematol. malignancies. We found that catalytic P300/CBP inhibition dynamically perturbs steady-state acetylation kinetics and suppresses oncogenic transcriptional networks in the absence of changes to chromatin accessibility. CRISPR-Cas9 screening identified NCOR1 and HDAC3 transcriptional co-repressors as the principal antagonists of P300/CBP by counteracting acetylation turnover kinetics. Finally, deacetylation of H3K27 provides nucleation sites for reciprocal methylation switching, a feature that can be exploited therapeutically by concomitant KDM6A and P300-CBP inhibition. Overall, this study indicates that the steady-state histone acetylation-methylation equilibrium functions as a mol. rheostat governing cellular transcription that is amenable to therapeutic exploitation as an anti-cancer regimen. This study involved multiple reactions and reactants, such as Ethyl 3-((6-(4,5-dihydro-1H-benzo[d]azepin-3(2H)-yl)-2-(pyridin-2-yl)pyrimidin-4-yl)amino)propanoate (cas: 1373423-53-0COA of Formula: C24H27N5O2).

Ethyl 3-((6-(4,5-dihydro-1H-benzo[d]azepin-3(2H)-yl)-2-(pyridin-2-yl)pyrimidin-4-yl)amino)propanoate (cas: 1373423-53-0) belongs to pyrimidine derivatives. Pyrimidines are isomeric with two other forms of diazines: pyridazine, with the nitrogen atoms in the 1 and 2 positions; and pyrazine, with the nitrogen atoms in the 1 and 4 positions. Pyrimidine derivatives have been used in a wide variety of pharmaceuticals including general anesthetics, anti-epilepsy medication, anti-malaria medication, drugs for treating high blood pressure, and HIV medication.COA of Formula: C24H27N5O2

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia